A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2017 According to a Spectrum Pharmaceuticals media release, data from the study will be presented an oral presentation at the 18th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer.
- 20 Jul 2017 Planned number of patients changed from 30 to 60.
- 02 May 2017 According to a Spectrum Pharmaceuticals media release, Interim results are expected before end of 2017.